Long non-coding RNA DLEU1 promotes papillary thyroid carcinoma progression by sponging miR-421 and increasing ROCK1 expression

Rui Li1*, Taihu Wan2*, Jie Qu3, Yang Yu4, Ruipeng Zheng5

1Department of Thyroid Surgery, The First Hospital of Jilin University, Changchun 130021, P.R. China
2Department of Division of Interventional Radiology, China-Japan Union Hospital of Jilin University, Changchun 130033, China
3Department of VIP Unit, China-Japan Union Hospital of Jilin University, Changchun 130033, China
4Department of General Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, China
5Department of Interventional Therapy, The First Hospital of Jilin University, Changchun 130021, P.R. China
*Equal contribution

Correspondence to: Yang Yu, Ruipeng Zheng; email: yuyang610697@jlu.edu.cn, zhengrp16@mails.jlu.edu.cn

Keywords: DLEU1, miR-421, papillary thyroid carcinoma, ROCK1

Received: February 3, 2019 Accepted: June 22, 2020 Published: September 10, 2020

INTRODUCTION

Thyroid cancer is a predominant endocrine neoplasm whose incidence rates are rapidly increasing in the last few decades [1]. The prognosis for patients with papillary thyroid carcinoma (PTC) is highly favorable, but, distant metastases or local recurrence is reported in several cases [2]. The potential molecular mechanisms that regulate metastasis in PTC are still unclear [3]. Hence, elucidating the molecular mechanisms involved in PTC growth and progression are critical and urgent in order to discover effective diagnostic and prognostic biomarkers and novel therapeutic targets for PTC.

Long noncoding RNAs (lncRNAs) are a class of regulatory RNA molecules without any coding capacity that are longer than 200 nucleotides [4]. LncRNAs are widely reported to regulate tumor cell growth, migration, invasion, and apoptosis in several cancers [5–7]. Previous studies have identified some lncRNAs that regulate PTC growth and metastasis and have been reported to be useful diagnostic and prognostic biomarkers and novel therapeutic targets [8, 9]. Therefore, there is great potential for lncRNAs as novel therapeutic targets in PTC.
Deleted in lymphocytic leukemia 1 (DLEU1) is a lncRNA that is located on chromosome 13q14.3, and is aberrantly upregulated in several malignancies, including osteosarcoma, hepatocellular carcinoma, bladder cancer, glioma, cervical cancer, pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer, and oral gastric cancer [10]. Besides, LDEU1 promotes tumor cell proliferation, migration, apoptosis and invasion in several cancers [10]. However, the role of DLEU1 in PTC is not clear. Hence, in this study, we investigated the role of DLEU1 in PTC growth and progression using PTC cell lines and patient tissue samples. We also investigated the plausible mechanisms through which DLEU1 regulates PTC growth and progression.

RESULTS

DLEU1 expression is significantly upregulated in PTC cell lines and tissues

Quantitative real time-PCR (qRT-PCR) analysis showed that DLEU1 expression was significantly higher in PTC tissues compared to matched adjacent noncancerous thyroid tissues from 54 PTC patients (Figure 1A). Next, we divided the 54 PTC patients into low (n=26) and high (n=28) DLEU expressing groups based on the mean DLEU1 expression in PTC tissues. Correlation analysis of DLEU1 expression and clinicopathological parameters showed that high DLEU1 expression was associated with lymph node metastasis and advanced TNM stages (Table 1). We then compared the expression of DLEU1 in human thyroid follicular epithelial cell line, Nthy-ori3-1 and four PTC cell lines, BHP5-16, TPC-1,8505C, and SW1736. QRT-PCR analysis showed higher DLEU1 expression in all PTC cell lines compared to the Nthy-ori 3-1 cells (Figure 1B). Furthermore, qRT-PCR analysis showed that DLEU1 expression was significantly higher in the cytoplasm compared to the nucleus in the TPC-1 cells (Figure 1C).

DLEU1 knockdown inhibits PTC cell proliferation, migration and invasion

We then analyzed the role of DLEU1 in tumorigenesis by evaluating the effects of DLEU1 knockdown on in vitro proliferation, migration and invasion of PTC cell lines. QRT-PCR analysis showed that DLEU1 levels were significantly reduced in sh-DLEU1-transfected TPC-1 cells compared to the sh-NC-transfected TPC-1 cells (Figure 2A). CCK8 assay results showed that proliferation was significantly reduced in the DLEU1-knockdown TPC-1 cells compared to the controls (Figure 2B). Furthermore, apoptosis was significantly increased in the DLEU1-knockdown TPC-1 cells compared to the controls (Figure 2C). Moreover, wound healing assay showed that cell migration was significantly reduced in DLEU1-knockdown TPC-1 cells compared to the controls (Figure 2D). Transwell invasion assay showed that invasiveness of DLEU1-knockdown TPC-1 cells was significantly reduced compared to the controls (Figure 2E).

DLEU1 sponges miR-421 in PTC cells

Next, we investigated potential DLEU1-binding miRNAs using the Starbase 2.0 online software and identified miR-421 as a potential candidate. Previous reports show that miR-421 is involved in the initiation and progression of multiple cancers, such as glioma, breast cancer, osteosarcoma and gastric cancer [11–14]. The sequence of miR-421 and the putative DLEU1-binding sites are shown in Figure 3A. Dual luciferase reporter assay showed that high luciferase activity was

Figure 1. DLEU1 is overexpressed in PTC tissues and cell lines. (A) QRT-PCR analysis shows the expression of DLEU1 in 54 paired PTC tissues and adjacent normal thyroid tissues. (B) QRT-PCR analysis shows the expression of DLEU1 in four PTC cell lines (BHP5-16, 8505C, TPC-1, and SW1736) and the human thyroid follicular epithelial cells, Nthy-ori3-1. (C) QRT-PCR analysis shows the expression of DLEU1 in the cytoplasmic and nuclear extracts of TPC-1 cells. Note: The data are shown as the means ± SD of at least three independent experiments. *P<0.05 and **P<0.01.
Table 1. Correlation between clinicopathological parameters and DLEU1 expression in PTC tissues.

| Variables                      | No. of cases | DLEU1 expression | P value |
|--------------------------------|--------------|------------------|---------|
|                                |              | High             | Low     |         |
| Age (years)                    |              |                  |         |         |
| <60                            | 22           | 10               | 12      | P=0.5804 |
| ≥60                            | 32           | 18               | 14      |         |
| Gender                         |              |                  |         |         |
| Male                           | 20           | 9                | 11      | P=0.5743 |
| Female                         | 34           | 19               | 15      |         |
| TNM stage                      |              |                  |         |         |
| T1-T2                          | 41           | 17               | 24      | P=0.0099 |
| T3-T4                          | 13           | 11               | 2       |         |
| Tumor size(cm)                 |              |                  |         |         |
| <1                             | 33           | 16               | 17      | P=0.5859 |
| ≥1                             | 21           | 12               | 9       |         |
| Lymph node metastasis          |              |                  |         |         |
| No                             | 39           | 15               | 24      | P=0.0020 |
| Yes                            | 15           | 13               | 2       |         |

found in TPC-1 cells co-transfected with miR-421 mimics and the wild-type DLEU1 luciferase reporter (WT-DLEU1), but was absent in TPC-1 cells transfected with miR-421 mimics and the mutant DLEU1 luciferase reporter (MUT-DLEU1) as shown in Figure 3B. RNA pull-down assay results showed that miR-421 DLEU1 directly binds to miR-421 in TPC-1 cells (Figure 3C). Moreover, miR-421 levels were significantly higher in DLEU1-knockdown TPC-1 cells compared to the controls (Figure 3D). The miR-421-mimic-transfected TPC-1 cells showed significantly lower levels of DLEU1 compared to the controls.

Figure 2. DLEU1 knockdown inhibits proliferation, migration and invasion of TPC-1 cells. (A) qRT-PCR analysis shows DLEU1 levels in sh-NC- and sh-DLEU1-transfected TPC-1 cells. (B) CCK8 assay results show proliferation rates of sh-NC- and sh-DLEU1-transfected TPC-1 cells. (C) Flow cytometry analysis shows the percentage apoptosis in sh-NC- and sh-DLEU1-transfected TPC-1 cells based on Annexin-V staining. (D) Wound healing assay results show the migration efficiency of sh-NC- and sh-DLEU1-transfected TPC-1 cells. (E) Transwell invasion assay results show the invasiveness of sh-NC- and sh-DLEU1-transfected TPC-1 cells. Note: The data is represented as the means ± SD of at least three independent experiments. *P< 0.05 and **P< 0.01.
(Figure 3E). Furthermore, miR-421 levels were significantly lower in PTC tissues compared to the adjacent normal thyroid tissues in 54 PTC patients (Figure 3F). Moreover, miR-421 expression was downregulated in all 4 PTC cell lines (BHP5-16, 8505C, TPC-1, and SW1736) compared to the Nthy-ori3-1 cells (Figure 3G). Besides, DLEU1 expression showed inverse correlation with miR-421 expression in PTC tissues (Figure 3H). These results demonstrate that DLEU1 directly binds and downregulates miR-421 in PTC cells and tissues.

**ROCK1 is a direct target of miR-421 in PTC cells**

Next, we searched for the target genes of miR-421 using the TargetScan software program and identified ROCK1-3'UTR as a potential miR-421 target (Figure 4A). Furthermore, dual luciferase reporter assay showed that luciferase activity was significantly decreased in TPC-1 cells co-transfected with reporter vector containing the wild-type ROCK1 3'-UTR (WT-ROCK1) and miR-421 mimics, but was not affected in TPC-1 cells transfected with a luciferase reporter vector with mutant ROCK1 3'-UTR (MUT-ROCK1) and miR-421 mimics (Figure 4B). Moreover, miR-421 overexpression significantly downregulated ROCK1 mRNA and protein levels in TPC-1 cells (Figure 4C and 4D). Besides, qRT-PCR analysis showed that ROCK1 mRNA levels were significantly higher in PTC tissues compared to adjacent normal thyroid tissues (Figure 4E). In PTC tissues, miR-421 expression negatively correlated with ROCK1 mRNA levels (Figure 4F, $r=-0.625$, $P<0.001$). These results confirm that miR-421 binds directly to the 3'UTR of ROCK1 in TPC-1 cells.

**DLEU1 modulates miR-421/ROCK1 axis in PTC cells**

We further investigated the association between DLEU1, miR-421 and ROCK1 in TPC-1 cells. Western blot analysis showed that ROCK1 protein levels were significantly reduced in sh-DLEU1-transfected TPC1 cells, but was reversed by co-transfection with the miR-421 inhibitor (Figure 5A). Moreover, DLEU1 levels showed positive correlation with ROCK1 in PTC tissues (Figure 5B). These results suggest that DLEU1 modulates the expression of ROCK1 by sponging miR-421 in PTC tissues and cells.

---

**Figure 3. DLEU1 sponges miR-421 in PTC cells.** (A) The diagram shows the predicted miR-421 binding sites in the 3'UTR of DLEU1 and the mutations in the miR-421 binding sites. (B) Dual luciferase reporter assay shows the relative luciferase activity of TPC-1 cells co-transfected with miR-421 mimic or miR-NC plus luciferase reporter plasmid with the wild-type DLEU1 (WT-DLEU1) or mutant DLEU1 (MUT-DLEU1). The miR-421 binding sites are mutated in the mutant DLEU1. (C) QRT-PCR results show DLEU1 levels in the RNA pull down extracts using biotinylated wild-type or mutant miR-421. (D) QRT-PCR analysis shows miR-421 levels in control and DLEU1-silenced TPC-1 cells. (E) QRT-PCR analysis shows DLEU1 levels in control and miR-421 mimic-transfected TPC-1 cells. (F) QRT-PCR analysis shows miR-421 expression in 54 paired PTC and adjacent normal thyroid tissues. (G) QRT-PCR analysis shows the expression of miR-421 in four PTC cell lines (BHP5-16, 8505C, TPC-1, and SW1736) and the human thyroid follicular epithelial cell line, Nthy-ori3-1. (H) Spearman’s correlation analysis shows that DLEU1 expression is inversely related to miR-421 expression in PTC tissues (n=54). Note: The data are represented as the means ± SD of at least three independent experiments. *$P<0.05$ and **$P<0.01$. 
Next, we analyzed if DLEU1 exerts its oncogenic effects in PTC via the miR-421/ROCK1 axis. CCK-8 assay results showed that proliferation was significantly reduced in DLEU1-silenced TPC-1 cells compared to the controls, but was partially rescued by overexpression of ROCK1 or miR-421 knockdown (Figure 5C). Furthermore, flow cytometry analysis demonstrated that apoptosis was significantly higher in DLEU1 knockdown TPC-1 cells, but was partially rescued by ROCK1 overexpression and miR-421 knockdown (Figure 5D). Collectively, these results suggest that DLEU1 promotes PTC cell proliferation and invasiveness via miR-421/ROCK1 axis.

**DLEU1 knockdown reduces in vivo xenograft PTC tumor growth**

Finally, we examined the in vivo effects of DLEU1 by establishing a xenograft tumor model through subcutaneous injection of control or DLEU1-knockdown TPC1 cells into nude mice. The tumor growth was significantly reduced in the sh-DLEU1 group compared to the sh-NC group (Figure 6A). The size and weight of xenograft tumors was significantly smaller in the sh-DLEU1 group compared to the sh-NC group (Figure 6B and 6C). IHC analysis of xenograft tumor tissue specimens showed that Ki-67- positive cells were significantly decreased in the sh-DLEU1 group tumors compared to those from the sh-NC group (Figure 6D). QRT-PCR analysis showed that DLEU1 and ROCK1 mRNA levels were reduced and miR-421 levels were higher in the sh-DLEU1 group tumors compared to the sh-NC group tumors (Figure 6E–6G). Western blot analysis showed that ROCK1 protein levels were reduced in the sh-DLEU1 group tumors compared to the sh-NC group tumors (Figure 6H).

**DISCUSSION**

Several lncRNAs act as tumor suppressors or oncogenes and regulate PTC growth and progression [8, 9]. Yin et al. demonstrated that lncRNA HOXA11-AS sponges miR-761, which suppresses PTC progression by

---

Figure 4. ROCK1 is a direct target of miR-421 in PTC cells. (A) The predicted miR-421 binding sites in the 3’UTR of ROCK1 and the mutated sequence are shown. (B) Dual luciferase reporter assay shows the relative luciferase activity in TPC-1 cells co-transfected with miR-421 mimic or miR-NC and luciferase reporter plasmid with wild-type ROCK1-3’-UTR (WT-ROCK1) or mutant ROCK1-3’-UTR (MUT-ROCK1). (C) QRT-PCR analysis shows the ROCK1 mRNA levels in miR-NC- and miR-421 mimic-transfected TPC-1 cells. (D) Western blot analysis shows ROCK1 protein levels in miR-NC- and miR-421 mimic-transfected TPC-1 cells. (E) QRT-PCR analysis shows ROCK1 mRNA expression in 54 paired PTC and adjacent normal thyroid tissues. (F) Spearman correlation analysis shows that ROCK1 expression is inversely related to miR-421 expression in PTC tissues (n=54). Note: The data are represented as the means ± SD of at least three independent experiments. *P< 0.05 and **P< 0.01.
Figure 5. DLEU1 regulates PTC cell growth and progression through the miR-421/ROCK1 axis. (A) Western blot analysis shows ROCK1 protein levels in sh-NC, sh-DLEU1- and sh-DLEU1 plus miR-421 inhibitor-transfected TPC-1 cells. (B) Spearman correlation analysis shows that ROCK1 mRNA expression is inversely related to DLEU1 expression in PTC tissues (n=54). (C) CCK-8 assay analysis shows proliferation rates of TPC-1 cells transfected with sh-NC, sh-DLEU1, sh-DLEU1 plus miR-421 inhibitor, and sh-DLEU1 plus ROCK1 overexpression plasmid. (D) Flow cytometry analysis shows percentage apoptosis (% Annexin-V+ cells) in TPC-1 cells transfected with sh-NC, sh-DLEU1, sh-DLEU1 plus miR-421 inhibitor, and sh-DLEU1 plus ROCK1 overexpression plasmid. (E) Wound healing assay results show the numbers of migrating cells in the TPC-1 cells transfected with sh-NC, sh-DLEU1, sh-DLEU1 plus miR-421 inhibitor, and sh-DLEU1 plus ROCK1 overexpression plasmid. (F) Transwell invasion assay results show the numbers of invading cells in the TPC-1 cells transfected with sh-NC, sh-DLEU1, sh-DLEU1 plus miR-421 inhibitor, and sh-DLEU1 plus ROCK1 overexpression plasmid. Note: The data is represented as the means ± SD of at least three independent experiments. *P< 0.05 and **P< 0.01.
targeting TRIM29 [15]. Tong et al. demonstrated that ZFAS1 promotes PTC progression by sponging miR-590-3p and upregulating HMGA2 [16]. Zhuang et al. showed that IncRNA ABHD11-AS1 promotes PTC progression by regulating the miR-199a-5p/SLC1A5 axis [17]. In this study, we demonstrate that DLEU1 promotes PTC progression by regulating the miR-421/ROCK1 axis.

DLEU1 is upregulated in several cancers, including non-small cell lung cancer [18], gastric cancer, clear cell renal cell carcinoma [19], glioma [20], bladder cancer [21], hepatocellular carcinoma [22], breast cancer [23], colorectal cancer [24], ovarian cancer [25] and cervical cancer [26]. While DLEU1 acts as an oncogene in these cancers, its regulatory mechanism and biological role in PTC is not clear. In the current study, we demonstrate that DLEU1 is up-regulated in both PTC cell lines and tissues. Furthermore, high DLEU1 levels correlate with poor prognosis of PTC patients. DLEU1 knockdown suppresses in vitro PTC cell proliferation and invasion, and inhibits xenograft tumor growth in the nude model mice. These results suggest that DLEU1 plays an oncogenic role in PTC.

Figure 6. DLEU1 knockdown reduces in vivo growth of xenograft tumors in nude mice model. (A) The curve shows the rate of growth of xenograft tumors generated from subcutaneously injected control and DLEU1 knockdown TPC-1 cells in the nude mice (n=5 each). Tumor growth was measured every 7 days for 28 days. (B) The representative images show the xenograft tumors in nude mice that are subcutaneously injected with control and DLEU1 knockdown TPC-1 cells for 28 days. (C) The histogram plot shows the weight of xenograft tumors derived from nude mice subcutaneously injected with control and DLEU1 knockdown TPC-1 cells. (D) Representative images show IHC staining with the anti-Ki67 antibody of xenograft tumor tissue sections derived from nude mice subcutaneously injected with control and DLEU1 knockdown TPC-1 cells. (E–F) QRT-PCR analysis shows the levels of DLEU1 and miR-421 in the xenograft tumor tissues derived from nude mice subcutaneously injected with control and DLEU1 knockdown TPC-1 cells. (E) Representative images show ROCK1 mRNA levels in the xenograft tumor tissues derived from nude mice subcutaneously injected with control and DLEU1 knockdown TPC-1 cells. (G) Western blot analysis shows ROCK1 protein levels in the xenograft tumor tissues derived from nude mice subcutaneously injected with control and DLEU1 knockdown TPC-1 cells. Note: The data are represented as the means ± SD of at least three independent experiments. *P<0.05 and **P<0.01.
LncRNAs act as competing endogenous RNAs and regulate gene transcription by sponging miRNAs and inhibiting their ability to bind to their target miRNAs [27, 28]. Previous studies show that DLEU1 acts as a ceRNA for miR-4429 [29], miR-671-5p [30], miR-133a [22], miR-99b [21], miR-300 [23] and miR-490-3p [24]. We used the Starbase 2.0 software to search for DLEU1-binding miRNAs and identified miR-421 as a potential target of DLEU1. Previous reports demonstrate that miR-421 regulates the growth and progression of glioma, breast cancer, osteosarcoma and gastric cancer [11–14]. In our study, dual luciferase and RNA pull down assays, and DLEU1 knockdown experiments confirmed that DLEU1 binds directly to miR-421 and inhibit its expression in PTC cells. Moreover, we demonstrate that miR-421 expression negatively correlates with DLEU1 levels in the PTC tissues. Furthermore, DLEU1-knockdown TPC-1 cells show increased apoptosis and decreased proliferation and migration, but these effects are partially rescued by inhibiting miR-421. These data suggest that DLEU1 promotes growth and progression of PTC by inhibiting miR-421 expression and function.

We also demonstrate that MiR-421 inhibits ROCK1 expression by directly binding to the 3′-UTR of ROCK1 in PTC cells. ROCK1 functions as an oncogene in many cancer types, such as non-small lung cancer, breast cancer, ovarian cancer and prostate cancer [31, 32]. ROCK1 is overexpressed in PTC tissues and promotes PTC cell proliferation and invasion [33, 34]. Previous reports also show that miR-26a [35], miR-584 [36] and miR-150 [37] directly target ROCK1 in PTC. We demonstrate that knockdown of DLEU1 decreases ROCK1 expression in TPC-1 cells, but, this effect is reversed by co-transfection with the miR-421 inhibitor. Moreover, ROCK1 expression negatively correlatives with miR-421 levels and positive correlates with DLEU1 levels in PTC tissues. ROCK1 overexpression partially rescues the reduced proliferation, migration and invasion of DLEU1-knockdown TPC-1 cells. These results demonstrate that DLEU1 exerts its oncogenic role in PTC by regulating the miR-421/ROCK1 axis.

In conclusion, our study demonstrates that DLEU1 promotes PTC growth and progression by regulating the miR-421/ROCK1 axis. Our data suggests that DLEU1 is a potential therapeutic target for PTC.

MATERIALS AND METHODS

PTC patient tissue samples

We obtained fresh paired PTC and adjacent non-tumor thyroid tissues from 54 PTC patients who underwent surgery at our hospital between March 2017 and March 2018. The samples were verified by pathological examination and stored at -80 °C until further use in experiments. These 54 patients did not receive any anti-tumor treatments before surgery. We obtained signed informed consent from all patients. The study was approved by the Ethics committee of the Jilin University.

PTC cell lines and transfection protocols

We purchased 4 human PTC cell lines, BHP5-16,8505C, TPC-1, SW1736, and Nthy-ori3-1 from the Chinese Academy of Sciences (Beijing, China). The cell lines were cultured in DMEM medium (Gibco, CA, USA) supplemented with heat-inactivated 10% fetal bovine serum (FBS, Gibco) and antibiotics (100 U/mL penicillin and 100 mg/mL streptomycin) (Gibco) in a incubator with 5% CO₂ at 37°C. The shRNA against DLEU1 (sh-DLEU1) and the negative control shRNA (sh-NC) were designed and synthesized by Shanghai Gene Pharma (Shanghai, China), and cloned into the pHBLV-U6-ZSGreen-puro lentivirus vector (HANBIO, Shanghai, China). Then, we infected the TPC-1 cells with lentiviral particles containing the shRNAs and selected the transfected cells by growing them in medium containing 1 μg/mL puromycin (Sigma, USA) for 7 days. The negative control mimics (miR-NC) and Hsa-miR-421 mimics (miR-421) were purchased from RiboBio (Guangzhou, China). The ROCK1 over-expressing plasmid vector (pCDNA3.1-ROCK1) was purchased from Western Biotechnology (Chongqing, China). The TPC-1 cells were transfected at 50%–70% confluence with pCDNA3.1 control vector, pCDNA3.1-ROCK1, miR-NC or miR-421 using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s recommendations.

Quantitative real-time PCR (qRT-PCR)

We extracted total cellular RNA and miRNA from cultured cells or tumor tissue sections using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and miRNA Isolation Kit (Qiangen, German), respectively. The miR-421 expression was examined as described previously [11]. To analyze the levels of DLEU1 and ROCK1 mRNA, cDNA was synthesized from total cellular or tissue RNA. Then, qPCR analysis was performed using the PrimeScript RT Reagent Kit (Takara). GAPDH and U6 were used as internal controls for DLEU1 or ROCK1 and miR-421, respectively. The qPCR primers for DLEU1, ROCK1 and miR-421 were as previously described [18, 11, 34]. The relative expression of DLEU1, ROCK1 mRNA and miR-421 was calculated using the 2^ΔΔCt method.

To determine DLEU1 levels in the cytoplasm and nuclei, we isolated cytoplasm and the nuclei using the...
Nuclear/Cytosol Fractionation Kit (Biovision, San Francisco, CA, USA) according to manufacturer’s instructions. Then, we extracted the total RNA from the cytoplasmic and the nuclear extracts and quantified DLEU1 by qRT-PCR using U6 and GAPDH as internal controls for nucleus and cytoplasm, respectively.

CCK-8 cell proliferation assay

CCK-8 assay was performed to determine the proliferation of different experimental groups of TPC-1 cells. Briefly, the transfected TPC-1 cells (10^4 cells / well) in RPMI 1640 with 10% FBS were seeded into 96-well plates and grown for 24 h in a humidified chamber at 37°C and 5% CO_2. Then, 10 μl CCK-8 solution was added to each well at different time points (24 h, 48 h and 72 h) and the cells were further incubated for another 4 h. Then, the optical density (OD) was measured at 450 nm using a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA) to determine the rate of proliferation.

Flow cytometry analysis of apoptosis analysis

We performed flow cytometry analysis to determine apoptotic rate of different experimental groups of TPC-1 cells using the Annexin V/Dead Cell Apoptosis Kit (Invitrogen) according to manufacturer’s instructions. The stained cells were analyzed using a MACSQuant™ Flow Cytometer (Miltenyi Biotec, USA) and the percentages of apoptotic (Annexin-V+) cells in each sample was determined using the Cell Quest software version 3.2 (BD Biosciences, USA).

Wound healing assay

To determine the role of miR-421 on tumor cell migration, we performed wound healing assay by seeding 5.0 x 10^4 transfected TPC-1 cells per well in 6-well plates. When the cultures reached confluence, an area of cells was wounded with a pipette tip. Then, after rinsing with PBS, the cells were further incubated in serum-free medium for 24 h. Images were captured under a light microscope(Olympus, Tokyo, Japan) at 0 and 24 h to determine the extent of wound healing. The wounded area was measured using the Image J software 3.0.

Transwell invasion assay

We performed Transwell invasion assay to determine the role of miR-421 on tumor cell invasiveness. Briefly, transfected TPC-1 cells were seeded in the upper chamber of the BD BioCoat™Matrigel invasion chambers (BD Biosciences) in serum-free DMEM medium. In the lower chamber, 600 μl of DMEM medium plus 10% FBS was added as a chemoattractant. The Transwell chambers were incubated for 24 h in a humidified chamber at 37°C and 5% CO_2. Then, the cells that invaded onto the lower side of the Transwell membrane between the upper and lower chambers were fixed, stained with crystal violet solution, and counted in 6 randomly chosen fields using a X71 Olympus light microscope.

Dual luciferase reporter assays

We cloned the wild-type (WT) or mutant (MUT) miR-421 binding sequences in the 3'UTR of ROCK1 (WT-ROCK1 and MUT-ROCK1) and DLEU1 (WT-DLEU1 and MUT-DLEU1) into the pGL3-promoter vector. The TPC-1 cells were co-transfected with the luciferase reporter vectors carrying different constructs and the miR-421 mimics or negative control mimics using the lipofectamine 2000 reagent (Invitrogen) according to manufacturer’s instructions. Luciferase activity was measured after 48 h using the Dual Luciferase Assay Kit (Promega, WI, USA) according to the manufacturer’s instructions.

RNA pull-down assays

For the RNA pull-down assay, TPC-1 cells were transfected with biotinylated wild type (WT) miR-421(Bio-WT-miR-421), mutant (MUT) miR-421(Bio-MUT-miR-421) and negative control (Bio-miR-NC) (Guangzhou RiboBio Co., Ltd). The cell lysates were collected at 24 h after transfection and incubated with Dynabeads M-280 Streptavidin (Invitrogen) for 3 h at 4 °C following the manufacturer’s protocol. Finally, DLEU1 levels were estimated in the RNA pull down extract using qRT-PCR.

Western blotting

Total cellular or tissue protein lysates were prepared using the RIPA lysis buffer with 1% protease inhibition from Sigma-Aldrich (Darmstadt, Germany) and quantified. Then, 20 μg of total protein lysates from each specimen was separated on a 10% SDS-PAGE and transferred using the semi-dry transfer method onto PVDF membranes (Billerica). Then, the membranes were blocked with 5% skimmed milk in TBST at room temperature for 1 h. The membranes were incubated overnight at 4°C with primary antibodies against ROCK1 and GAPDH (Santa Cruz Biotechnology, CA, USA), followed by incubation at room temperature for 1 h with HRP-conjugated secondary antibodies(Santa Cruz Biotechnology). The protein blots were developed using the ECL (Enhanced Chemiluminescence) Detection Kit (BOSTER, USA). ROCK1 levels relative to GAPDH1 were quantified using the Image J software.
Xenograft tumor model

The animal experiments were performed in accordance with the protocol approved by the Institutional Animal Care and Use Committee review board of Jilin University. We subcutaneously injected $5 \times 10^6$ stably transfected sh-NC- or sh-DLEU1-transfected TPC1 cells into the left flanks of 5-6 week old female nude mice (18-25g; $n=5$). Tumor volume ($V$) was measured once a week using the following formula: $V = (\text{Length} \times \text{Width}^2)/2$. Then, after 28 days, the mice were euthanized. The tumors were harvested, weighed, and stored for qRT-PCR and immunohistochemistry (IHC).

Immunohistochemistry (IHC)

IHC was performed to detect Ki-67 expression in the xenograft tumors as described previously [38]. The primary rabbit anti-Ki-67 antibody and the secondary goat anti-rabbit IgG were purchased from Abcam (Cambridge, UK). Ki-67 expression was quantified using the Image-pro-plus (IPP) software (Media Cybernetics, Washington, USA).

Statistical analysis

The data is shown as the means ± SD (standard deviation) from at least three independent experiments. Statistical analysis was performed using the SPSS software version 19.0 (IBM SPSS, Armonk, NY, USA). The continuous data was compared using the Student’s two-tailed t-test for 2 groups and one-way analysis of variance (ANOVA) for more than 2 groups. Spearman correlation analysis was used to determine the relationship between DLEU1, miR-421 and ROCK1 expression. The Chi–square test was used to analyze the correlation between DLEU1 expression and the clinicopathological parameters of PTC patients. $P<0.05$ was considered statistically significant.

AUTHOR CONTRIBUTIONS

YY and RZ made substantial contributions to the conception and design of the study and critically revised it for important intellectual content. RL and TW contributed to the acquisition of the data. JQ analyzed and interpreted the data. All authors read and approved the final manuscript.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest.

FUNDING

This study did not receive any specific funding.

REFERENCES

1. Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer. 2001; 85:1335–39. https://doi.org/10.1054/bjoc.2001.2061 PMID:11720471
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11–30. https://doi.org/10.3322/caac.21166 PMID:23335087
3. Pemayun TG. Current diagnosis and management of thyroid nodules. Acta Med Indones. 2016; 48:247–57. PMID:27840362
4. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Presnner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015; 47:199–208. https://doi.org/10.1038/ng.3192 PMID:25599403
5. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009; 136:629–41. https://doi.org/10.1016/j.cell.2009.02.006 PMID:19239885
6. Corrà F, Agnoletto C, Minotti L, Baldassari F, Volinia S. The network of non-coding RNAs in cancer drug resistance. Front Oncol. 2018; 8:327. https://doi.org/10.3389/fonc.2018.00327 PMID:30211115
7. Balas MM, Johnson AM. Exploring the mechanisms behind long noncoding RNAs and cancer. Noncoding RNA Res. 2018; 3:108–17. https://doi.org/10.1016/j.ncrna.2018.03.001 PMID:30175284
8. Sedaghati M, Kebebew E. Long noncoding RNAs in thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2019; 26:275–81. https://doi.org/10.1097/MED.0000000000000497 PMID:31385810
9. Murugan AK, Munirajan AK, Alzahrani AS. Long noncoding RNAs: emerging players in thyroid cancer pathogenesis. Endocr Relat Cancer. 2018; 25:R59–82. https://doi.org/10.1530/ERC-17-0188 PMID:29146581
10. Song C, Zhang J, Zhao Z, Yang Y, Meng D, Wang J, Guo C, Yuan C. DLEU1: a functional long noncoding RNA in tumorigenesis. Curr Pharm Des. 2020; 26:1742–48. https://doi.org/10.2174/1381612826666200122145305 PMID:31969095
11. Liu L, Cui S, Zhang R, Shi Y, Luo L. MiR-421 inhibits the Malignant phenotype in glioma by directly targeting MEF2D. Am J Cancer Res. 2017; 7:857–68. PMID: 28469958

12. Wang Y, Liu Z, Shen J. MicroRNA-421-targeted PDCD4 regulates breast cancer cell proliferation. Int J Mol Med. 2019; 43:267–75. https://doi.org/10.3892/ijmm.2018.3932 PMID: 30365117

13. Zhou S, Wang B, Hu J, Zhou Y, Jiang M, Wu M, Qin L, Yang X. miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma. Tumour Biol. 2016; 37:9001–07. https://doi.org/10.1007/s13277-015-4578-5 PMID: 26758431

14. Zhou H, Xiao B, Zhou F, Deng H, Zhang X, Lou Y, Gong Z, Du C, Guo J. MiR-421 is a functional marker of circulating tumor cells in gastric cancer patients. Biomarkers. 2012; 17:104–10. https://doi.org/10.3109/1354750X.2011.64961 PMID: 22263628

15. Yin X, Zhang J, Li C, Zhang Z, Jin T, Song L, Zhang R, Wang W, Tao Y, Wang X. LncRNA HOXA11-AS accumulation-induced microRNA-761 downregulation regulates cell growth by targeting TRIM29 in papillary thyroid cancer. Am J Transl Res. 2019; 11:6826–37. PMID: 31814890

16. Tong H, Zhuang X, Cai J, Ding Y, Si Y, Zhang H, Shen M. Long noncoding RNA ZFAS1 promotes progression of papillary thyroid carcinoma by sponging miR-590-3p and upregulating HMGA2 expression. Onco Targets Ther. 2019; 12:7501–12. https://doi.org/10.2147/OTT.S209138 PMID: 31571903

17. Zhuang X, Tong H, Ding Y, Wu L, Cai J, Si Y, Zhang H, Shen M. Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis. Cell Death Dis. 2019; 10:620. https://doi.org/10.1038/s41419-019-1850-4 PMID: 31409775

18. Zhang S, Guan Y, Liu X, Ju M, Zhang Q. Long non-coding RNA DLEU1 exerts an oncogenic function in non-small cell lung cancer. Biomed Pharmacother. 2019; 109:985–90. https://doi.org/10.1016/j.biopha.2018.10.175 PMID: 30551552

19. He GZ, Yu SY, Zhou QP, Chen ML, Zhang YW, Zheng Y, Zhang ZB, Han ZY, Yu J. LncRNA DLEU1 accelerates the Malignant progression of clear cell renal cell carcinoma via regulating miRNA-194-5p. Eur Rev Med Pharmacol Sci. 2019; 23:10691–98. https://doi.org/10.26355/eurrev_201912_19768 PMID: 31858537

20. Feng L, He M, Rao M, Diao J, Zhu Y. Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D axis. Onco Targets Ther. 2019; 12:5405–14. https://doi.org/10.2147/OTT.S207542 PMID: 31360066

21. Li Y, Shi B, Dong F, Zhu X, Liu B, Liu Y. Long non-coding RNA DLEU1 promotes cell proliferation, invasion, and confers cisplatin resistance in bladder cancer by regulating the miR-99b/HS3ST3B1 axis. Front Genet. 2019; 10:280. https://doi.org/10.3389/fgen.2019.00280 PMID: 30984249

22. Zhang W, Liu S, Liu K, Liu Y. Long non-coding RNA deleted in lymphocytic leukaemia 1 promotes hepatocellular carcinoma progression by sponging miR-133a to regulate IGF-1R expression. J Cell Mol Med. 2019; 23:5154–64. https://doi.org/10.1111/jcmm.14384 PMID: 3107081

23. Wang C, Xie XX, Li WJ, Jiang DQ. LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells. Eur Rev Med Pharmacol Sci. 2019; 23:10410–21. https://doi.org/10.26355/eurrev_201912_19680 PMID: 31841195

24. Liu T, Han Z, Li H, Zhu Y, Sun Z, Zhu A. LncRNA DLEU1 contributes to colorectal cancer progression via activation of KPNA3. Mol Cancer. 2018; 17:118. https://doi.org/10.1186/s12943-018-0873-2 PMID: 30098595

25. Wang LL, Sun KX, Wu DD, Xiu YL, Chen X, Chen S, Zong ZH, Sang XB, Liu Y, Zhao Y. DLEU1 contributes to ovarian carcinoma tumourigenesis and development by interacting with miR-490-3p and altering CDK1 expression. J Cell Mol Med. 2017; 21:3055–65. https://doi.org/10.1111/jcmm.13217 PMID: 28598010

26. Lee S, Luo W, Shah T, Yin C, O’Connell T, Chung TH, Perkins SL, Miles RR, Ayello J, Morris E, Harrison L, van de Ven C, Cairo MS. The effects of DLEU1 gene expression in burkitt lymphoma (BL): potential mechanism of chemoinmunotherapy resistance in BL. Oncotarget. 2017; 8:27839–53. https://doi.org/10.18632/oncotarget.15711 PMID: 28427156

27. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfo P. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell. 2011; 146:353–58. https://doi.org/10.1016/j.cell.2011.07.014 PMID: 21802130
28. Klinge CM. Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers. Endocr Relat Cancer. 2018; 25:R259–82. https://doi.org/10.1530/ERC-17-0548 PMID:29440232

29. Liu X, Chen R, Liu L. SP1-DLEU1-miR-4429 feedback loop promotes cell proliferative and anti-apoptotic abilities in human glioblastoma. Biosci Rep. 2019; 39:BSR20190994. https://doi.org/10.1042/BSR20190994 PMID:31713587

30. Chen X, Zhang C, Wang X. Long noncoding RNA DLEU1 aggravates osteosarcoma carcinogenesis via regulating the miR-671-5p/DDX5 axis. Artif Cells Nanomed Biotechnol. 2019; 47:3322–28. https://doi.org/10.1080/21691401.2019.1648285 PMID:31379208

31. Wei L, Surma M, Shi S, Lambert-Cheatham N, Shi J. Novel insights into the roles of rho kinase in cancer. Arch Immunol Ther Exp (Warsz). 2016; 64:259–78. https://doi.org/10.1007/s00005-015-0382-6 PMID:26725045

32. Liu K, Li X, Wang J, Wang Y, Dong H, Li J. Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer. Oncotarget. 2017; 8:19298–309. https://doi.org/10.18632/oncotarget.15197 PMID:28184030

33. Li R, Dong B, Wang Z, Jiang T, Chen G. MicroRNA-361-5p inhibits papillary thyroid carcinoma progression by targeting ROCK1. Biomed Pharmacother. 2018; 102:988–95. https://doi.org/10.1016/j.biopha.2018.03.122 PMID:29710554

34. Luo D, Chen H, Li X, Lu P, Long M, Peng X, Lin S, Tan L, Zhu Y, Ouyang N, Li H. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma. Int J Onkol. 2017; 51:1209–18. https://doi.org/10.3892/ijo.2017.4100 PMID:28848996

35. Wu YC, Li SY, Jia YF. MicroRNA-26a suppresses the Malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway. Eur Rev Med Pharmacol Sci. 2019; 23:8940–49. https://doi.org/10.26355/eurrev_201910_19292 PMID:31696481

36. Xiang J, Wu Y, Li DS, Wang ZY, Shen Q, Sun TQ, Guan Q, Wang YJ. miR-584 Suppresses Invasion and Cell Migration of Thyroid Carcinoma by Regulating the Target Oncogene ROCK1. Oncol Res Treat. 2015; 38:436–40. https://doi.org/10.1159/000438967 PMID:26405762

37. Cheng L, Zhou R, Chen M, Feng L, Li H. MicroRNA-150 targets rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in papillary thyroid carcinoma. Mol Med Rep. 2017; 16:2217–24. https://doi.org/10.3892/mmr.2017.6842 PMID:28656254

38. Chen Y, Gao H, Li Y. Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-β1/smads signaling pathway. Mol Cell Endocrinol. 2020; 500:110634. https://doi.org/10.1016/j.mce.2019.110634 PMID:31678422